α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease

Tracy Cole(Ionis Pharmaceuticals (United States)), Katrina L. Paumier(Michigan State University)

JCI Insight

March 7, 2021

10.1172/jci.insight.135633

Cited by 136

Related Papers

Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease

|bioRxiv (Cold Spring Harbor Laboratory)|2019|10